If you have heard of Ozempic, you have heard of Semaglutide. The two are the same molecule, marketed under different names depending on whether the prescription is for diabetes or for obesity. The thing nobody on TikTok mentions is how interesting the molecule actually is, and how different the experience of taking it is from the way it gets described.
What it actually is
Semaglutide is the third generation of a drug class called GLP-1 receptor agonists. The first was exenatide (Byetta), approved in 2005, originally derived from a hormone first isolated in Gila monster venom. The second was liraglutide (Victoza, then Saxenda), which lasted long enough to dose once daily. Semaglutide is the first in the class with a half-life long enough to dose weekly, which changed the entire experience of using it.
The molecule is a 31-amino-acid peptide that mimics glucagon-like peptide 1, a hormone your gut releases in response to a meal. The trick that makes it last so long is a fatty acid side chain attached to one of the amino acids. That side chain binds reversibly to albumin in your bloodstream, which acts as a slow-release reservoir.
How it works
GLP-1 has receptors in three places that matter for what semaglutide does. The first is the pancreas, where it tells beta cells to release insulin in response to glucose, and tells alpha cells to dial back glucagon. This is the diabetes mechanism, and the original reason this drug class existed.
The second is the stomach. GLP-1 slows gastric emptying. Food sits in your stomach longer. You feel full faster and stay full longer. This is the part you notice in the first month, when meals you used to finish suddenly feel impossible halfway through.
The third is the brain. There are GLP-1 receptors in the hypothalamus and brainstem. A population of neurons in the arcuate nucleus called POMC neurons signal satiety. Another population called AgRP neurons signal hunger. GLP-1 increases POMC firing and decreases AgRP firing. The subjective experience users describe as their food noise quieting is what it feels like when those two populations stop arguing.
What the trials show
The pivotal weight loss trial was STEP-1, published in NEJM in 2021. It enrolled 1,961 adults without diabetes, BMI 30 or higher, and randomized them to 2.4mg semaglutide weekly versus placebo, plus lifestyle counseling, for 68 weeks. The treatment group lost an average of 14.9 percent of body weight. The placebo group lost 2.4 percent. About 86 percent of the treatment group lost at least 5 percent of body weight, half lost at least 15 percent, and a third lost at least 20 percent.
STEP-3 layered intensive behavioral therapy on top of the same dose, with the result that the treatment effect bumped up to about 16 percent. STEP-4 was the discontinuation trial. People who had lost weight on semaglutide for 20 weeks were randomized either to continue or to switch to placebo. The continuation arm kept losing. The placebo arm regained roughly two thirds of the weight they had lost within a year.
That last result is the most important number to keep in mind. Semaglutide is not a one-time intervention. The weight comes back when you stop, because the underlying biology has not changed. The drug fixes a hunger setpoint that, for many people with obesity, is structurally elevated. Take the fix away, the setpoint reverts.
What you actually feel
The first month is the hardest. Nausea is reported by something like 44 percent of users in trials. Most of it is dose-dependent, which is why the titration schedule exists: start at 0.25mg, increase to 0.5 after four weeks, then 1.0, 1.7, and finally 2.4. By the time you reach the maintenance dose your body has adapted to most of the GI effects.
What you also feel, and what trials do not fully capture, is a kind of mental quiet around food. People describe it as food not being interesting anymore. Snacks lose appeal. The internal monologue about what to eat next stops running. If you have spent your life arguing with your appetite, this experience can feel almost spiritual. If you have a complicated relationship with food, it can feel disorienting.
The side effect picture
Beyond the GI symptoms, there are real risks worth understanding. Pancreatitis shows up in about 0.1 to 0.2 percent of users in long-term trials. Gallbladder problems, especially gallstones, increase by about 1 to 2 percent over background risk, partly because rapid weight loss is itself a gallbladder risk factor. Both warrant immediate attention if abdominal pain develops.
Rodent studies showed an increased rate of medullary thyroid carcinoma at supratherapeutic doses. No human signal has emerged in the years since approval, but the FDA black-box warning means anyone with a personal or family history of MTC, or anyone with multiple endocrine neoplasia type 2, should not use this drug.
The other thing worth knowing about is muscle loss. Roughly 25 to 40 percent of weight lost on semaglutide is lean mass when no resistance training is done. Adding resistance training and adequate protein during the loss phase substantially reduces this. The cosmetic version of this concern is what people call Ozempic face: the loss of facial fat that accompanies overall fat loss can age the face by years if no countermeasures are taken.
Who it is for
On paper: BMI 30 or higher, or BMI 27 with at least one weight-related comorbidity. In practice, anyone serious about losing significant weight who has not been able to do it through behavior change alone is a reasonable candidate, with a doctor's involvement.
It is not for: pregnancy, type 1 diabetes, history of MTC or MEN2, severe gastroparesis, or anyone who cannot tolerate the GI burden. It is also not for anyone looking for a quick fix without a long-term plan, because the regain when you stop is real and substantial.
The honest closing
Semaglutide is the first drug in any class that consistently produces weight loss in the same range as bariatric surgery. That is a serious thing to say about a peptide. It is also a serious commitment to make. The decision to start it is not the decision to take it for six months. It is the decision to either take it indefinitely or to use the runway to rebuild your habits hard enough that you can hold a new setpoint when you come off.
See it on you
What none of this answers is what 12 weeks on Semaglutide could look like on your specific body. PepScan does. Snap one photo, pick Semaglutide, and you see a photoreal projection of your transformation. It is the part of the decision you cannot read your way to.